A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this first-in-human, open-label, multicenter, non-randomized study is to
investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and
preliminary clinical activity of ES002023 in patients with advanced solid tumors that are
relapsed or refractory to standard therapies.